Σάββατο 7 Μαΐου 2016

UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016

JKGD (1) grant/research support - Dompe pharmaceuticals, SiFi Pharmaceuticals (non-specific); MA-J (1) commissioned work – Genus Pharmaceuticals (non-specific); (2) sponsorship to conferences – Abbvie, Janssen-Cilag, Pfizer, Galderma, Steifel (non-specific); (3) clinical trials - Zymogenetics, Pfizer, Genentech, Johnson & Johnson, Centocor, Novartis (non-specific); (4) grant/research support – Emblation (non-specific); (5) developed non-profit website www.drugrash.co.uk to assist clinicians in management of drug allergy (specific).

from #ENT via xlomafota13 on Inoreader http://ift.tt/1NmDHk0
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου